Garwood Medical Devices Announces Series C Funding
Summary
The minimally invasive BioPrax device is in evaluation to help eliminate biofilm infections on prosthetic joints during early-intervention procedures. In in vivo animal models, BioPrax has shown a 99.6% biofilm reduction with no increased bone or tissue damage as compared to antibiotics alone, which achieved only 81.17% reduction. FDA granted BioPrax Breakthrough Device Designation in 2019. "The COVID-19 pandemic has forever changed the healthcare system and is motivating medical professionals to reevaluate all treatment standards," said Wayne Bacon, Garwood Medicals CEO. "During this time of reinvention, hospital administrators are actively seeking out new technologies that have the potential to support the delivery of safe, effective treatment options with the least amount of risk to patients."